China’s securities regulators on Thursday set the stage for the resumption of mainland initial public offerings by granting approval to a relatively small market debut from Guilin Sanjin Pharmaceutical Company, official Chinese press reported.

The listings approval from the China Securities Regulatory Commission is the first since last September and the company is likely to be among the first to list on the mainland exchanges in nearly 10 months. Some 32 other companies are planning to come to the market when the CSRC lifts its moratorium on listings, which is expected imminently.